Kymera Therapeutics (KYMR) Operating Leases (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Operating Leases of $65.6 million for Q1 2026, down 7.86% year-over-year from $71.2 million in Q1 2025, and down 2.16% quarter-over-quarter from $67.0 million in Q4 2025.
Kymera Therapeutics (KYMR) Operating Leases (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Operating Leases for 8 consecutive years, with $65.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 7.86% year-over-year to $65.6 million; the TTM figure through Mar 2026 stood at $65.6 million (down 7.86% YoY), while the FY2025 annual figure was $67.0 million, down 7.44% from the prior year.
- Operating Leases slipped to $65.6 million in Q1 2026 per KYMR's latest filing, from $67.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $77.0 million in Q4 2023 and bottomed at $12.1 million in Q4 2022.
- Historically, Operating Leases has averaged $57.5 million across 5 years, with a median of $69.8 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Leases fell 8.15% — and 2023, when it soared 534.18%.
- Kymera Therapeutics' Operating Leases stood at $12.1 million in 2022, then jumped by 534.18% to $77.0 million in 2023, then dropped by 5.98% to $72.4 million in 2024, then dropped by 7.44% to $67.0 million in 2025, then slipped by 2.16% to $65.6 million in 2026.
- Business Quant data shows KYMR's Operating Leases at $65.6 million in Q1 2026, $67.0 million in Q4 2025, and $68.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.02 Mn |
| Mar 31, 2026 | 65.59 Mn |
| Dec 31, 2025 | 67.03 Mn |
| Sep 30, 2025 | 68.45 Mn |
| Jun 30, 2025 | 69.84 Mn |
| Mar 31, 2025 | 71.18 Mn |
| Dec 31, 2024 | 72.42 Mn |
| Sep 30, 2024 | 73.64 Mn |
| Jun 30, 2024 | 74.82 Mn |
| Mar 31, 2024 | 75.98 Mn |
| Dec 31, 2023 | 77.03 Mn |
| Sep 30, 2023 | 76.61 Mn |
| Jun 30, 2023 | 70.50 Mn |
| Mar 31, 2023 | 63.88 Mn |
| Dec 31, 2022 | 12.15 Mn |
| Sep 30, 2022 | 12.43 Mn |
| Jun 30, 2022 | 12.71 Mn |
| Mar 31, 2022 | 12.98 Mn |
| Dec 31, 2021 | 13.22 Mn |
| Sep 30, 2021 | 13.46 Mn |